Trials / Completed
CompletedNCT00622388
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
An Open-label, Single-arm. Multi-center Phase 2 Trial With Ofatumumab in Patients With Relapsed/Progressive Diffuse Large B-Cell Lymphoma (DLBCL) Ineligible for Transplant or Relapse/Progression After Autologous Transplant
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 81 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine the effect of ofatumumab in patients with Diffused Large B-Cell Lymphoma (DLBCL) ineligible for transplant or relapsed after autologous transplant
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ofatumumab | 8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg |
Timeline
- Start date
- 2007-12-01
- Primary completion
- 2010-05-01
- Completion
- 2014-08-01
- First posted
- 2008-02-25
- Last updated
- 2015-07-24
- Results posted
- 2011-09-08
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00622388. Inclusion in this directory is not an endorsement.